Clinical trials with adriamycin

205Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Adriamycin was given to 67 patients with a variety of tumors. The tolerated dose was 20–30 mg/m2/day IV daily for 3 days or 18 mg/m2/day IV daily for 5 days every 3 weeks. Objective responses were seen in transitional cell carcinoma (4/7), liposarcoma (2/2), squamous cell carcinoma (1/9), and adenocarcinoma of the breast (1/1). No responses were seen in other soft tissue sarcomas (10), malignant melanoma (4), acute leukemia (4), lymphoepithelioma (1), or tumors of the gastrointestinal organs (5), thyroid (2), kidney (4), and testis (2). At low doses, nausea and vomiting, phlebitis, and alopecia appeared. At higher doses, mucositis and myelosuppression seem related to the dose of each course, while EKG changes (4 cases) and congestive heart failure (6 cases) appear related to the cumulative dose. EKG changes, consisting of premature ventricular contractions and ST‐T wave changes, appeared to be related to adriamycin in 3 cases. The CHF appeared related in 3 cases. Adriamycin appears to be promising in several tumors, but maintenance therapy may be precluded by cumulative toxicity. Copyright © 1971 American Cancer Society

References Powered by Scopus

Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia

407Citations
N/AReaders
Get full text

Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic

241Citations
N/AReaders
Get full text

Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease

192Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A clinicopathologic analysis of adriamycin cardiotoxicity

1406Citations
N/AReaders
Get full text

Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?

374Citations
N/AReaders
Get full text

Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high‐dosage schedule

354Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Middleman, E., Luce, J., & Frei, E. (1971). Clinical trials with adriamycin. Cancer, 28(4), 844–850. https://doi.org/10.1002/1097-0142(1971)28:4<844::AID-CNCR2820280407>3.0.CO;2-9

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 22

92%

Lecturer / Post doc 1

4%

Researcher 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 16

59%

Biochemistry, Genetics and Molecular Bi... 5

19%

Agricultural and Biological Sciences 4

15%

Pharmacology, Toxicology and Pharmaceut... 2

7%

Save time finding and organizing research with Mendeley

Sign up for free